- News Home
5 December 2013 11:26 am ,
Vol. 342 ,
An animal rights group known as the Nonhuman Rights Project filed lawsuits in three New York courts this week in an...
Researchers have been hot on the trail of the elusive Denisovans, a type of ancient human known only by their DNA and...
Thousands of scientists in the Russian Academy of Sciences (RAS) are about to lose their jobs as a result of the...
Dyslexia, a learning disability that hinders reading, hasn't been associated with deficits in vision, hearing, or...
Exotic, elusive, and dangerous, snakes have fascinated humankind for millennia. They can be hard to find, yet their...
Researchers have sequenced and analyzed the first two snake genomes, which represent two evolutionary extremes. The...
Snake venoms are remarkably complex mixtures that can stun or kill prey within minutes. But more and more researchers...
At age 30, Dutch biologist Freek Vonk has built up a respectable career as a snake scientist. But in his home country,...
- 5 December 2013 11:26 am , Vol. 342 , #6163
- About Us
New Vaccine Research Effort Launched as Advocate Steps Down
8 June 2011 4:11 pm
The vaccine world's revolving door took a fast spin today as the head of the Global HIV Vaccine Enterprise announced his retirement and a new foundation for vaccine research was born.
Alan Bernstein, who took over the helm at the New York-based Global HIV Vaccine Enterprise in 2008, helped the then fledgling organization join together researchers, funders, and advocates. Under his tenure, the enterprise formed a secretariat, published a strategic plan to guide the field, and started a program for young investigators. "I feel like I've accomplished a lot of what I set out to do," Bernstein told ScienceInsider. "It's time for new leadership, and I'm a strong believer in passing the torch."
Bernstein, who previously headed the Canadian Institutes of Health Research, plans to take a few months off before exploring new job options. José Esparza, the senior advisor on HIV vaccines at the Bill & Melinda Gates Foundation, will serve as interim president until the board selects a new one.
Meanwhile, scientists and advocates for all vaccine research today launched yet another effort to increase funding and coordination. The Foundation for Vaccine Research, based in Washington, D.C., has recruited a board stacked with several prominent HIV/AIDS researchers, including Ronald Desrosiers of the New England Primate Research Center, Simon Wain-Hobson of the Institut Pasteur in Paris, and Robin Weiss of University College London.
Peter Hale, an advertising specialist who has long worked with HIV/AIDS researchers, started the foundation. "No one has been campaigning or lobbying for all vaccine research, and it's desperately needed," says Hale. "The science and technology are there, but the resources aren't." He plans to organize telethons to raise funding, which he says then will be awarded to grants that review committees will evaluate rapidly. "There are teams of scientists out there crying out for money, and we've only had two major sources of funds, the U.S. National Institutes of Health and the Gates Foundation," says Hale.
The foundation also wants to confront the prevalence of misinformation on vaccines that has convinced thousands of new parents to forgo vaccination for their babies. "It's a huge issue, and somebody needs to take it on," Hale says. "Nobody, with the exception of a few brave individuals like Paul Offitt—who is on our board—has done it yet."